Related Experiment Video
Updated: Feb 8, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
Published on: March 17, 2020
MicroRNA-1297 contributes to the progression of human cervical carcinoma through PTEN
Zhihua Chen1, Mengzhen Zhang1, Yuhuan Qiao1
1a The First Affiliated Hospital of Zhengzhou University , Zhengzhou , China.
Background:
The human cervical carcinoma oncogenic mechanisms still remain elusive. Thus, we proposed to understand the biological role of a newly discovered therapeutic miRNA.
Methods:
MiR-1297 related to human cervical carcinoma was selected for this study. TaqMan qRT- PCR assay was used to profile miRNA, phosphatase and tensin homolog (PTEN) expression in randomly chosen tumour with non-tumour tissues, and the apoptosis factors expression. Cell proliferation was monitored by CCK-8 assay and colony formation assay. Apoptosis was determined by flow cytometry. Protein level was determined by western blotting. 3'UTR was performed to validate the direct binding sites of miR-1297 on PTEN. SPSS was used for statistical analyses.
Results:
MiR-1297 is repressed and PTEN activated in human cervical cancer tissues. After miR-1297 overexpression, HeLa cells had an increase in cell proliferation and decrease in apoptosis. PTEN expression is negatively correlation with miR-1297. PTEN silencing display the similar pattern as miRNA-1297 overexpression to inhibit HeLa cell growth and apoptosis in vitro.
Conclusions:
Our data indicate that miR-1297 contribute to the human cervical carcinoma through PTEN. miR-1297 could be a reasonable miRNA for future studies.
Insights
This study reveals microRNA-1297 (miR-1297) is repressed in cervical cancer, promoting tumor growth by activating phosphatase and tensin homolog (PTEN). MiR-1297 may be a therapeutic target for human cervical carcinoma.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Human cervical carcinoma oncogenic mechanisms are not fully understood.
- A newly discovered therapeutic microRNA (miRNA) was investigated for its biological role.
- Understanding miRNA's role is crucial for developing new cervical cancer therapies.
Purpose of the Study:
- To elucidate the biological role of miR-1297 in human cervical carcinoma.
- To investigate the relationship between miR-1297 and phosphatase and tensin homolog (PTEN) in cervical cancer.
- To determine if miR-1297 can be a therapeutic target for cervical cancer.
Main Methods:
- Quantitative real-time PCR (qRT-PCR) to profile miR-1297 and PTEN expression.
- Cell proliferation assays (CCK-8, colony formation) and flow cytometry for apoptosis analysis.
- Western blotting and 3'UTR assays to validate miR-1297 targeting of PTEN.
Main Results:
- MiR-1297 was found to be repressed, while PTEN was activated in human cervical cancer tissues.
- Overexpression of miR-1297 in HeLa cells led to increased proliferation and decreased apoptosis.
- PTEN silencing mimicked miR-1297 overexpression effects, inhibiting cell growth and apoptosis.
Conclusions:
- MiR-1297 contributes to human cervical carcinoma development by targeting PTEN.
- MiR-1297 demonstrates potential as a therapeutic miRNA for cervical cancer.
- Further research into miR-1297 is warranted for its clinical application.
More Related Videos
07:44Non-Invasive Ultrasound Assessment of Endometrial Cancer Progression in Pax8-Directed Deletion of the Tumor Suppressors Arid1a and Pten in Mice
Published on: February 17, 2023
15:43Experimental Generation of Carcinoma-Associated Fibroblasts CAFs from Human Mammary Fibroblasts
Published on: October 25, 2011
Related Concept Videos
MicroRNAs
MicroRNAs
Binet's Contribution to Measures of Intelligence
Wechsler's Contribution to Measures of Intelligence
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...